Replimune skin cancer drug that became FDA flashpoint is rejected again Virus-based treatment became part of debate over shifting agency standards

https://www.statnews.com/2026/04/10/skin-cancer-replimune-fda-approval/ By Jason MastApril 10, 2026 General Assignment Reporter